Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| GlaxoSmithKline | 2.57% | $467.58K | £91.50B | 51.88% | 77 Outperform | |
| ― | 2.53% | $459.24K | ― | ― | ― | |
| Roche Holding AG | 2.46% | $447.65K | CHF294.84B | 43.28% | 73 Outperform | |
| Bristol-Myers Squibb | 2.37% | $430.89K | $121.64B | 5.82% | 78 Outperform | |
| BAE Systems | 2.33% | $422.84K | £61.53B | 77.31% | 61 Neutral | |
| Yum China Holdings | 2.31% | $420.60K | $20.06B | 17.90% | 78 Outperform | |
| Melrose | 2.15% | $391.16K | £8.55B | 8.03% | 50 Neutral | |
| Koninklijke Philips N.V. | 2.14% | $389.54K | €25.29B | 7.75% | 56 Neutral | |
| Thales | 2.13% | $387.18K | €53.33B | 40.69% | 73 Outperform | |
| Spirax Group | 2.12% | $385.62K | £5.80B | 2.56% | 72 Outperform |